This article summarizes the importance of different targets such as 5α-reductase,
17β-HSD, CYP17A, androgen receptor and protein kinase A for the treatment of prostate
cancer and benign prostatic hyperplasia. It is a well known fact that dihydrotestosterone
(DHT) is associated with the development of androgen-dependent afflictions. At the present
time, several research groups are attempting to develop new steroidal and non-steroidal
molecules with the purpose of inhibiting the synthesis and biological response of DHT. This review also discusses
the most recent studies reported in the literature that describe the therapeutic potential of novel compounds,
as well as the new drugs, principally inhibitors of 5α-reductase.
Keywords: Benign prostatic hyperplasia, prostate cancer, 5-alpha reductase, 17-beta hydroxysteroid dehydrogenase,
protein kinase A, androgen receptor, dehydroepiandrosterone derivatives, non-permeable testosterone conjugates,
G proteins, PKA.
open access plus
Rights & PermissionsPrintExport